The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors.
 
Sara Federico
No Relationships to Disclose
 
Daniel Morgenstern
Honoraria - HMP; Ology Medical Education; Takeda Israel Ltd
Consulting or Advisory Role - Abbvie; Clarity Pharmaceuticals; RayzeBio; Regeneron; US World Meds; Ymabs Therapeutics Inc
Speakers' Bureau - Takeda Israel Ltd; Ymabs Therapeutics Inc
Research Funding - Abbvie (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cellectar (Inst); Lilly (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Abbvie
(OPTIONAL) Uncompensated Relationships - Oncoheroes Biosciences
 
Sarah Cohen-Gogo
No Relationships to Disclose
 
Clinton Stewart
Research Funding - Ipsen (Inst); Pfizer (Inst)
 
Haitao Pan
No Relationships to Disclose
 
Jessica Gartrell
No Relationships to Disclose
 
Sara Helmig
No Relationships to Disclose
 
Allison Pribnow
No Relationships to Disclose
 
Teresa Santiago
No Relationships to Disclose
 
Zachary Abramson
No Relationships to Disclose
 
Kris Ann Schultz
No Relationships to Disclose
 
Jennie Foster
Consulting or Advisory Role - US WorldMeds; Ymabs Therapeutics Inc
 
Victor Santana
No Relationships to Disclose
 
Alberto Pappo
Honoraria - Bayer; Lilly; Pfizer; Roche
Consulting or Advisory Role - Debbio; EUSA Pharma; Lilly; Loxo/Bayer; Merck; Pfizer
 
Elizabeth Stewart
No Relationships to Disclose